2.37
2.37 (0%)
As of Feb 14, 2025
Black Diamond Therapeutics, Inc. [BDTX]
Source:
Company Overview
Black Diamond Therapeutics, Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (617) 252-0848 |
| Industry | manufacturing |
| CEO | Mark A. Velleca |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-78.8 |
| Net Income | $-69.7 |
| Net Cash | $-19.8 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -49.6% |
| Profit as % of Stockholder Equity | -83.7% |
Management Effectiveness
| Return on Equity | -83.7% |
| Return on Assets | -56.8% |
| Turnover Ratio | |
| EBITA | $-78.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $122.6 |
| Total Liabilities | $39.4 |
| Operating Cash Flow | $-62.3 |
| Investing Cash Flow | $17 |
| Financing Cash Flow | $25.5 |
